18Nov 2023
Nivolumab for Patients With High-Risk Oral Leukoplakia

Nivolumab for Patients With High-Risk Oral Leukoplakia

A recent nonrandomized, open-label phase 2 clinical trial investigated the safety and efficacy of nivolumab in treating proliferative verrucous leukoplakia (PVL), a high-risk oral precancerous condition. The study demonstrated a positive response in 36% of patients, suggesting potential clinical activity for nivolumab in PVL. Despite 27% developing oral squamous cell carcinoma during the trial, the findings offer valuable insights for future research on this challenging-to-treat precancerous disease.

  • #oncology

Like

Save

Share